Will showcase cutting-edge technologies shaping the future of optoelectronics and accelerated computing -- Ongoing demonstrations March 17-19 at Los Angeles Convention Center BOSTON, March 05, 2026 ...

IgA nephropathy (IgAN) is a kidney condition where antibodies (immune system proteins) build up and cause damage in your kidneys. IgAN, also known as Berger's disease, does not have a cure. However, ...

Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...

Novartis has spent considerable time and energy building its presence in the IgA nephropathy (IgAN) disease area, and now it can celebrate a key trial win for its first drug to gain an FDA approval in ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME). Their anti-tumor functions include recognizing tumor-associated antigens, ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease caused by problems in the body's complement system, which normally helps fight infections. It damages tiny filters in your kidneys called ...

Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...

IgA nephropathy is the most common primary glomerulonephritis globally, impacting roughly 25-50 per million people annually. This chronic kidney disease occurs when immunoglobulin A (IgA) deposits ...

The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line. The FDA Wednesday granted an accelerated approval to Novartis’ Fabhalta in IgAN. The ...